Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > Market to double next 8 yrs
View:
Post by biggdogg on Nov 21, 2024 6:16pm

Market to double next 8 yrs

The market for contrast media is experiencing rapid growth at a rate of 7.4% and is expected to double within the next 8 years, reaching $12 billion. Voyageur is poised to benefit from this long-term bull market. This growth is crucial for their drug development initiatives, particularly as the potential value of new drugs successfully transitioning past phase one trials is expected to be substantially higher than other drugs, as value is based on market size. Additionally, the projected doubling of the barium market further underscores the significance of this growth trend, with a 7.4% growth rate representing a considerably high rate of expansion.
In the context of pharmaceutical consumables, a 7.4% growth rate is generally considered significant and relatively high. Pharmaceutical markets often have more modest growth rates compared to other industries, making a 7.4% growth rate notably high. This rate of growth indicates increasing demand, market expansion, and potentially lucrative opportunities for Voyageur.
The critical minerals required for contrast media will never keep up to demand at this rate. Why anyone would sell this stock is mind blowing.
https://www.gminsights.com/industry-analysis/contrast-media-market
Comment by WarrantOfficer on Nov 22, 2024 9:18am
Those are some great numbers. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1